Jones Olcay Y
Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.
Department Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Children (Basel). 2024 Sep 22;11(9):1146. doi: 10.3390/children11091146.
This communication summarizes our single-center experience with the use of anti-IL-1 biologic response modifiers for treating autoimmune and autoinflammatory conditions in children.
We outline our rationale for the off-label use of anakinra and discuss emerging treatment paradigms that necessitate further research and validation.
Anakinra has enabled personalized treatment, whether used as a single agent on an as-needed basis, as part of a background treatment regimen, or in combination with colchicine. Our data also highlight the significance of anakinra in treating post-infectious inflammatory diseases, demonstrating its high efficacy in novel applications such as rheumatic fever and post-viral arthritis. Canakinumab, on the other hand, has provided long-term remission. Both medications were well-tolerated, with no serious adverse effects reported.
Based on our observations and successful outcomes, we advocate for future collaborative efforts to improve access to anti-IL-1 medications to better manage excessive and harmful inflammation in children.
本交流总结了我们单中心使用抗白细胞介素-1生物反应调节剂治疗儿童自身免疫性和自身炎症性疾病的经验。
我们概述了非标签使用阿那白滞素的基本原理，并讨论了需要进一步研究和验证的新兴治疗模式。
阿那白滞素实现了个性化治疗，无论是按需作为单一药物使用、作为背景治疗方案的一部分，还是与秋水仙碱联合使用。我们的数据还突出了阿那白滞素在治疗感染后炎症性疾病中的重要性，证明了其在风湿热和病毒感染后关节炎等新应用中的高效性。另一方面，卡那单抗实现了长期缓解。两种药物耐受性良好，未报告严重不良反应。
基于我们的观察和成功结果，我们倡导未来开展合作，以增加抗白细胞介素-1药物的可及性，从而更好地控制儿童过度且有害的炎症。
